COMPANY

Xalud Therapeutics

HQ: Charlottesville, VA source · xaludthera.com ↗

Keywords: neurology gene therapy inflammatory diseases Knee Osteoarthritis Amyotrophic Lateral Sclerosis Facet Joint Pain Back Pain Inflammation Neuropathic Pain Spine Osteoarthritis XT-150

Location: Charlottesville, VA · source · Jun 2, 2021

Profile checked Oct 10, 2026

8Trials (company is sponsor)

Timeline

2027-03 Trial start Phase 1: Safety Study of XT-150 in Participants With ALS source ↗
Feb 24, 2022 Trial start Phase 2: Safety and Efficacy of XT-150 for Facet Joint Osteoarthritis Pain source ↗
2021-10 Trial start Phase 1/Phase 2: Preliminary Safety and Efficacy of XT-150 in Facet Joint Osteoarthritis source ↗
Apr 14, 2021 Trial start Phase 1: Safety and Efficacy of XT-150 for Treatment of Neuropathic Pain source ↗
Feb 14, 2020 Trial start Phase 2: Efficacy and Safety of XT-150 in Osteoarthritis of the Knee source ↗
Mar 20, 2019 Trial start Phase 1: Follow on Extension of XT-150-1-0201 source ↗
Jun 8, 2018 Trial start Phase 1: Safety, Tolerability, and Efficacy of XT-150 for the Treatment of Osteoarthritic Pain source ↗
Mar 21, 2018 Trial start Phase 1: Preliminary Evaluation of Safety, Tolerability, and Efficacy of XT-150 for the Treatment of Osteoarthritic Pain source ↗

Upcoming milestones

2028-06 (ESTIMATED) · Phase 1 · Safety Study of XT-150 in Participants With ALS · NCT06704347

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 8

Record	Title	Phase	Status	Start	Primary completion
NCT06704347	Safety Study of XT-150 in Participants With ALS	Phase 1	Not yet recruiting	2027-03	2028-06 (estimated)
NCT04124042	Efficacy and Safety of XT-150 in Osteoarthritis of the Knee	Phase 2	Completed	Feb 14, 2020	Apr 26, 2022 (actual)
NCT05196919	Safety and Efficacy of XT-150 for Facet Joint Osteoarthritis Pain	Phase 2	Completed	Feb 24, 2022	Sep 20, 2023 (actual)
NCT04466410	Safety and Efficacy of XT-150 for Treatment of Neuropathic Pain	Phase 1	Terminated	Apr 14, 2021	Sep 27, 2022 (actual)
NCT04841512	Preliminary Safety and Efficacy of XT-150 in Facet Joint Osteoarthritis	Phase 1/Phase 2	Withdrawn	2021-10	Mar 1, 2022 (actual)
NCT03769662	Follow on Extension of XT-150-1-0201	Phase 1	Completed	Mar 20, 2019	Oct 30, 2019 (actual)
NCT03477487	Safety, Tolerability, and Efficacy of XT-150 for the Treatment of Osteoarthritic Pain	Phase 1	Completed	Jun 8, 2018	Jul 19, 2019 (actual)
NCT03282149	Preliminary Evaluation of Safety, Tolerability, and Efficacy of XT-150 for the Treatment of Osteoarthritic Pain	Phase 1	Completed	Mar 21, 2018	Mar 31, 2019 (actual)